Tenaya Therapeutics to update on pivotal plans for heart gene therapies by year end, CEO says at Meeting on the Mesa
Tenaya CEO Faraz Ali said the company will update on pivotal trial talks for TN-201 in HCM and TN-401 in ARVC by the end of 2026, citing interim data that Ali said showed reduced hypertrophy and arrhythmia burden.
